The gliflozins vary in SGLT1 inhibitory potency, especially sotagliflozin (Table 2), which is a dual SGLT1/2 inhibitor that reduces postprandial and fasting blood glucose in patients with types 1 or 2 diabetes [21,22]. The gene discussed is SLC5A1; the disease is diabetes mellitus.